Odyssean LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

Odyssean LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,957	Closed	-$1.51M	–	555
2026 Q1	$1.51M	Buy	1,957 +989	+102%	+$757K	0.55%	15
2025 Q4	$747K	Buy	+968	New	+$657K	0.54%	44

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Odyssean LLC's REGN Position: Q2 2026 in Review

Odyssean LLC sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 1,957 shares — an estimated $1.51M sold.

Odyssean LLC first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $1.51M in Q1 2026. 1,328 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Odyssean LLC reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Odyssean LLC sold 1,957 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.51M.
Odyssean LLC first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Odyssean LLC's Regeneron Pharmaceuticals position peaked at $1.51M in Q1 2026.
1,328 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Odyssean LLC's 13F filing for Q2 2026, filed 14 Aug 2026.